Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029 (NASDAQ:XENE)
· seekingalpha.com
Xenon (XENE) Q2 2026 earnings call: FDA pre-NDA aligned; azetukalner NDA due this quarter, pipeline and cash runway to 2029.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...